Skip to main content

Table 2 Patients' characteristics according to ICIs initiation within 30 days of death

From: PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

 

Control

ICIs started within 30 days of death

 

N° (%)

N° (%)

532 (93.8)

35 (6.2)

Age

   

 < 60 years old

142 (26.7)

6 (17.1)

P = 0.2132

P = 0.2810

 ≥ 60 years old

390 (73.3)

29 (82.9)

 < 70 years old

300 (56.4)

23 (65.7)

 ≥ 70 years old

232 (43.6)

12 (34.3)

Gender

  

P = 0.7536

 Female

181 (34.0)

11 (31.4)

 Male

351 (66.0)

24 (68.6)

ECOG PS

  

P < 0.0001

 0—1

455 (85.5)

19 (54.3)

 ≥ 2

77 (14.5)

16 (45.7)

Primary tumor

  

P = 0.0172

 NSCLC

324 (60.9)

28 (80)

 Melanoma

108 (20.3)

3 (8.6)

 Renal cell carcinoma

82 (15.4)

1 (2.9)

 Others

18 (3.4)

3 (8.6)

No. of metastatic sites

  

P = 0.0095

 ≤ 2

208 (39.1)

6 (17.1)

 > 2

324 (60.9)

29 (82.9)

Treatment line

  

P = 0.1822

 First

158 (29.7)

15 (42.9)

 Second

306 (57.5)

18 (51.4)

 Further lines

68 (12.8)

2 (5.7)

  1. ICI: immune checkpoint inhibitor; ECOG-PS: eastern cooperative oncology group-performance status; NSCLC: non-small cell lung cancer